Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 21,000 shares, a decrease of 44.9% from the December 15th total of 38,100 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average daily volume of 291,600 shares, the days-to-cover ratio is currently 0.1 days.

Evogene Stock Down 1.9 %

EVGN stock traded down $0.03 during mid-day trading on Tuesday, reaching $1.52. 13,947 shares of the stock traded hands, compared to its average volume of 41,668. The business has a 50-day moving average of $1.63 and a two-hundred day moving average of $3.04. The firm has a market capitalization of $8.15 million, a PE ratio of -0.34 and a beta of 1.30. Evogene has a 52 week low of $1.20 and a 52 week high of $10.40.

Institutional Trading of Evogene

A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC purchased a new stake in Evogene Ltd. (NASDAQ:EVGN) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of Evogene in a research report on Monday. They issued a “sell” rating on the stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.